Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Expression analysis of extracellular microRNA in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.

Kishore A, Navratilova Z, Kolek V, Novosadova E, Čépe K, du Bois RM, Petrek M.

Respirology. 2018 Dec;23(12):1166-1172. doi: 10.1111/resp.13364. Epub 2018 Jun 29.

PMID:
29956871
2.

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.

Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM.

Eur Respir J. 2017 May 19;49(5). pii: 1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.

3.

Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis.

Betteridge ZE, Woodhead F, Lu H, Shaddick G, Bunn CC, Denton CP, Abraham DJ, du Bois RM, Lewis M, Wells AU, McHugh NJ.

Arthritis Rheumatol. 2016 Nov;68(11):2778-2783. doi: 10.1002/art.39755.

4.

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM.

Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.

5.

Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia.

Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Blumhagen RZ, Schwarz MI, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch DA, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Murphy E, Smith K, McKean D, Pedersen BS, Talbert J, Powers J, Markin CR, Beckman KB, Lathrop M, Freed B, Langefeld CD, Schwartz DA.

BMC Genet. 2016 Jun 7;17(1):74. doi: 10.1186/s12863-016-0377-2.

6.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

7.

Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.

Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):711-8. doi: 10.1164/rccm.201508-1546OC.

8.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.

9.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

10.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

11.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”.

Eur Respir J. 2015 Oct;46(4):976-87. doi: 10.1183/13993003.00150-2015. Epub 2015 Jul 9.

12.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.

13.

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis.

Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR.

Eur Respir J. 2015 May;45(5):1374-81. doi: 10.1183/09031936.00146314. Epub 2015 Jan 22.

14.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
15.

6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis.

du Bois RM.

Eur Respir J. 2014 Jun;43(6):1823-4. doi: 10.1183/09031936.00002514. No abstract available.

16.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

17.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

18.

Genetic determinants of pulmonary fibrosis: evolving concepts.

Spagnolo P, Grunewald J, du Bois RM.

Lancet Respir Med. 2014 May;2(5):416-28. doi: 10.1016/S2213-2600(14)70047-5. Epub 2014 Apr 2. Review.

PMID:
24815806
19.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

20.

Approaches to the treatment of some of the troublesome manifestations of sarcoidosis.

Eklund A, du Bois RM.

J Intern Med. 2014 Apr;275(4):335-49. doi: 10.1111/joim.12198. Epub 2014 Feb 5. Review.

21.

Rare lung disease and orphan drug development.

Spagnolo P, du Bois RM, Cottin V.

Lancet Respir Med. 2013 Aug;1(6):479-87. doi: 10.1016/S2213-2600(13)70085-7. Epub 2013 Jun 25. Review.

PMID:
24429246
22.

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.

23.

Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data.

Zappala CJ, Desai SR, Copley SJ, Spagnolo P, Sen D, Alam SM, du Bois RM, Hansell DM, Wells AU.

Chest. 2014 Jan;145(1):101-107. doi: 10.1378/chest.12-2479.

PMID:
24051950
24.

Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung.

Antoniou KM, Walsh SL, Hansell DM, Rubens MR, Marten K, Tennant R, Hansel T, Desai SR, Siafakas NM, du Bois RM, Wells AU.

Respirology. 2013 Nov;18(8):1191-6. doi: 10.1111/resp.12154.

PMID:
23819865
25.

Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis.

Richeldi L, Collard HR, du Bois RM, Jenkins G, Kolb M, Maher TM, Raghu G, Vancheri C, Laurent GJ.

Eur Respir J. 2013 Jul;42(1):230-8. doi: 10.1183/09031936.00038613. Epub 2013 May 16.

26.

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwert SD, du Bois RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz MI, Schwartz DA.

Nat Genet. 2013 Jun;45(6):613-20. doi: 10.1038/ng.2609. Epub 2013 Apr 14. Erratum in: Nat Genet. 2013 Nov;45(11):1409.

27.

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ.

J Rheumatol. 2013 May;40(5):640-6. doi: 10.3899/jrheum.121043. Epub 2013 Mar 1.

28.

A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.

Vancheri C, du Bois RM.

Eur Respir J. 2013 Feb;41(2):262-9. doi: 10.1183/09031936.00115112. Epub 2012 Aug 16.

29.

Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.

du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW.

Am J Respir Crit Care Med. 2012 Oct 15;186(8):712-5. doi: 10.1164/rccm.201206-1010PP. Epub 2012 Jul 12.

PMID:
22798316
30.

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis.

du Bois RM.

Eur Respir Rev. 2012 Jun 1;21(124):141-6. doi: 10.1183/09059180.00000812. Review.

31.

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.

Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B; American Thoracic Society Committee on BAL in Interstitial Lung Disease.

Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14. doi: 10.1164/rccm.201202-0320ST.

PMID:
22550210
32.

Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease.

Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ.

Respir Med. 2012 Jul;106(7):1040-7. doi: 10.1016/j.rmed.2012.03.006. Epub 2012 Apr 12.

33.

Optimal scoring of serial change on chest radiography in sarcoidosis.

Zappala CJ, Desai SR, Copley SJ, Spagnolo R, Cramer D, Sen D, Alam SM, du Bois RM, Hansell DM, Wells AU.

Sarcoidosis Vasc Diffuse Lung Dis. 2011 Oct;28(2):130-8.

PMID:
22117504
34.

Idiopathic pulmonary fibrosis trials: recommendations for the jury.

Nathan SD, du Bois RM.

Eur Respir J. 2011 Nov;38(5):1002-4. doi: 10.1183/09031936.00068611. No abstract available.

35.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM.

N Engl J Med. 2011 Sep 22;365(12):1079-87. doi: 10.1056/NEJMoa1103690.

36.

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.

37.

Idiopathic pulmonary fibrosis: present understanding and future options.

du Bois RM.

Eur Respir Rev. 2011 Sep 1;20(121):132-3. doi: 10.1183/09059180.00001511. No abstract available.

38.

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.

Richeldi L, du Bois RM.

Expert Rev Respir Med. 2011 Aug;5(4):473-81. doi: 10.1586/ers.11.52. Review.

PMID:
21859266
39.

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM.

Chest. 2011 Jul;140(1):221-229. doi: 10.1378/chest.10-2572. Review.

PMID:
21729893
40.

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.

41.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group.

Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.

PMID:
21571362
42.

T-helper cell type-1 transcription factor T-bet is upregulated in pulmonary sarcoidosis.

Kriegova E, Fillerova R, Tomankova T, Hutyrova B, Mrazek F, Tichy T, Kolek V, du Bois RM, Petrek M.

Eur Respir J. 2011 Nov;38(5):1136-44. doi: 10.1183/09031936.00089910. Epub 2011 May 3. Erratum in: Eur Respir J. 2012 Jan;39(1):230.

43.

Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP.

Clin Vaccine Immunol. 2011 Jun;18(6):931-9. doi: 10.1128/CVI.00337-10. Epub 2011 Apr 20.

44.

A common MUC5B promoter polymorphism and pulmonary fibrosis.

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA.

N Engl J Med. 2011 Apr 21;364(16):1503-12. doi: 10.1056/NEJMoa1013660.

45.

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J.

Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7.

PMID:
21474646
46.

Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning?

Cerri S, du Bois RM, Spagnolo P.

Eur Respir J. 2011 Mar;37(3):489-91. doi: 10.1183/09031936.00160310. No abstract available.

47.

Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET.

Keijsers RG, Grutters JC, Thomeer M, Du Bois RM, Van Buul MM, Lavalaye J, Van Den Bosch JM, Verzijlbergen FJ.

Q J Nucl Med Mol Imaging. 2011 Feb;55(1):66-71. Epub 2011 Jan 18.

PMID:
21242947
48.

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7. doi: 10.1164/rccm.201007-1179OC. Epub 2010 Dec 3.

49.

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.

Goh NS, Desai SR, Anagnostopoulos C, Hansell DM, Hoyles RK, Sato H, Denton CP, Black CM, du Bois RM, Wells AU.

Eur Respir J. 2011 Jul;38(1):184-90. doi: 10.1183/09031936.00010910. Epub 2010 Oct 28.

50.

Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups.

Sato H, Woodhead FA, Ahmad T, Grutters JC, Spagnolo P, van den Bosch JM, Maier LA, Newman LS, Nagai S, Izumi T, Wells AU, du Bois RM, Welsh KI.

Hum Mol Genet. 2010 Oct 15;19(20):4100-11. doi: 10.1093/hmg/ddq325. Epub 2010 Aug 3.

Supplemental Content

Loading ...
Support Center